Drugs / MTX-463
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07450521 | Feb → Mar 2026 | — | Mediar Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06401213 | Apr → Nov 2024 | — | Mediar Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06967805 | May 2025 → Aug 2027 expected | idiopathic pulmonary fibrosis | Mediar Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTX-463 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07450521 ↗ |
| Modality | Monoclonal antibody | “immunoglobin G1 (IgG1) monoclonal antibody” NCT06401213 ↗ |
| Route | Intravenous | “by intravenous (IV) infusion” NCT06967805 ↗ |
| Target | WISP1 | “directed against WNT-inducible signaling pathway protein 1 (WISP1)” NCT06401213 ↗ |